阳光诺和诉恒生制药研发费用纠纷案一审胜诉 获判支付25.4万元及违约金

Core Viewpoint - Sunshine Nuohua Pharmaceutical Research Co., Ltd. has received a first-instance judgment regarding a contract dispute over R&D expenses with Hunan Hengsheng Pharmaceutical Co., Ltd., which requires Hengsheng to pay 254,000 yuan in overdue R&D fees and corresponding penalties, while rejecting other claims from Sunshine Nuohua [1][2]. Group 1 - The court ruled that Hengsheng must pay Sunshine Nuohua 254,000 yuan within fifteen days from the judgment's effective date, along with a penalty calculated at a 5% annual interest rate from November 23, 2022, until actual payment [1]. - Sunshine Nuohua has fully provisioned for bad debts related to the overdue amount, indicating that the lawsuit will not negatively impact the company's current or future profits [2]. - The case is still within the appeal period, allowing Hengsheng to appeal to the Hunan Provincial High People's Court within fifteen days of receiving the judgment, introducing uncertainty regarding the final execution of the ruling [2].